tbuckley/cabot-search huggingface dataset:
Safety and efficacy of cardiopoietic stem cells in the treatment of post-infarction left-ventricular dysfunction – From cardioprotection to functional repair in a translational pig infarction model
Authors: Maximilian Y. Emmert, Petra Wolint, Andras Jakab, Sean P. Sheehy, Francesco S. Pasqualini, Thi Dan Linh Nguyen, Monika Hilbe, Burkhardt Seifert, Benedikt Weber, Chad E. Brokopp, Dominika Macejovska, Etem Caliskan, Arnold von Eckardstein, Ruth Schwartlander, Viola Vogel, Volkmar Falk, Kevin Kit Parker, Mariann Gyöngyösi, Simon P. Hoerstrup
Journal: Biomaterials (2016)
AB1041 Household Ergonomics: Development and Validation of A Novel Tool To Assess Physical Exposures Contributing To Household Work Related Low Back Pain
Authors: P.D. Ranasinghe, I. Atukorala, A. Samaranayake, N.S. Gunawardana
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Household ergonomic risks-especially physical exposures straining the low back during manual household work can contribute to low back pain in housewives. To date, there are no screening tools to identify physical exposures that cause household work related low back pain. <h3>Objectives</h3> To develop and validate "Physical Exposure Check-Household work related low back pain (PEC-HLBP)", a tool to assess physical exposures contributing to household work related low back pain. <h3>Methods</h3> Items for PEC-HLBP were generated based on a theoretical framework developed through review of literature, qualitative observations and expert opinion. Item reduction was by a panel of 10 experts based on a scoring system. The draft PEC-HLBP was developed into an interviewer-administered questionnaire with responses in a Likert scale to facilitate responses on the gradient of the physical exposure and the scoring system adopted reflected the gradient of exposure. PEC-HLBP was designed to be answered based on household work activities routinely being performed by the respondent. Exploratory factor analysis using principal component analysis was performed on a sample of 250, 20–50 year old eligible housewives to further reduce items and to assess construct validity. Internal consistency and test retest assessed the reliability. <h3>Results</h3> The initial PEC-HLBP contained 36 items. Ten items which scored an average score less than 2 by the panel of experts (score based on the importance as a physical exposure on a 1–5 scale) were eliminated. Exploratory factor analysis of draft PEC-HLBP with 26 items showed 9 factors (Eigen values 1.008–5.163) explaining 64.18% of total variance. All 26 items in draft tool showed factor loadings above 0.4 not requiring further reduction of items. Two factors with items of similar loadings were amalgamated based on the theoretical framework. Finalized PEC-HLBP contained 26 items in eight domains which were assigned names to depict the items they contained (figure 1). Experiencing the physical exposures or not were determined based on a predetermined cut off score for each domain. The mean duration to complete the questionnaire was 16 (±4) minutes. Cronbach9s Alpha was 0.789 (95% CI 0.725–0.825).The test-retest reliability was good (Spearman`s coefficient above 0.77) for all domains. Response rate among housewives was 83.3% and the response rate for each question was 100% with no missing data. <h3>Conclusions</h3> PEC-HLBP is a valid, reliable and acceptable tool to assess physical exposures contributing to household work related low back pain among housewives <h3>Acknowledgement</h3> Medical Research Institute, Sri Lanka <h3>Disclosure of Interest</h3> None declared
Effects of Temperature on the Change of HSP and the Viability of Mobilized Hematopoietic Stem Cells.
Authors: Hawk Kim, Young Joo Min, Jin Ho Baek, Su Jin Shin, Eui-Kyu Noh, Eun-Hee Lee, Sang-Kyu Park, Jung Lim Lee, Jae-Hoo Park
Journal: Blood (2007)
Synergistic Interaction between Notch ligand Delta-1 and IL-6/Soluble IL-6 Receptor Fusion Protein in the Generation of BFU-E from Primitive Hematopoietic Progenitors.
Authors: Kentaro Yamamura, Kohshi Ohishi, Naoyuki Katayama, Hiroshi Shiku, Masahiro Masuya, Yuji Heike, Mitsuo Nishikawa, Tatsutoshi Nakahata
Journal: Blood (2004)
AB0370 Real Life Experience with Abatacept in Patients with Rheumatoid Arthritis from A Regional Centre in UK
Authors: P. Joshi, T.P. Sheeran, S. Venkatachalam, S. Roskell
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Abatacept is a biologic option for patient with Rheumatoid arthritis who have not responded to conventional disease modifying drugs as well as to TNF alpha inhibitors. It has been approved by the National Institute of Health and Clinical Excellence in UK. <h3>Objectives</h3> We share our experience with Abatacept in patients with Rheumatoid arthritis (RA) in routine clinical practice focussing on clinical response, disease remission and drug survival. <h3>Methods</h3> A retrospective analysis of RA patients on Abatacept from November 2012 to November 2014 was performed. Data collected included baseline demographics, number of previous synthetic and biologic DMARDs (Disease modifying drugs), baseline DAS 28 (Disease activity score) and change in DAS28 at 6 months. <h3>Results</h3> Total patients: 138 (100 females and 38 males, F: M ratio 2.63:1). Mean age of population was 63 years. Mean disease duration prior to abatacept was 12.8 years. Mean number of conventional DMARDs used before abatacept were 3.1 and biological DMARDs were 1.8. Abatacept was the first biological therapy used in 10 (7.2%) patients. At last follow up 59 (42.8%) and 57 (41.3%) patients were on intravenous and subcutaneous abatacept. Mean DAS score before starting abatacept 5.89. Clinical response with a change in DAS 28 &gt;1.2 was seen in 76% patients on Abatacept at 6 months. 15.9% Abatacept patients achieved remission at 6 months. 22 (15.9%) patients discontinued abatacept. Drug survival over 6 months was seen in 102 (73.9%) patients. <h3>Conclusions</h3> Abatacept showed response rate of 76% similar to reported in literature. Drug survival beyond 24 weeks was higher compared to other studies. Abatacept is safe, well tolerated and clinically effective in RA patients in real life. <h3>Disclosure of Interest</h3> None declared
National Registry Data and Record Linkage to Inform Postmarket Surveillance of Prosthetic Aortic Valve Models Over 15 Years
Authors: Graeme L. Hickey, Ben Bridgewater, Stuart W. Grant, John Deanfield, John Parkinson, Alan J. Bryan, Malcolm Dalrymple-Hay, Neil Moat, Iain Buchan, Joel Dunning
Journal: JAMA Internal Medicine (2016)

Postmarket evidence generation for medical devices is important yet limited for prosthetic aortic valve devices in the United Kingdom.To identify prosthetic aortic valve models that display unexpected patterns of mortality or reintervention using routinely collected national registry data and record linkage.This observational study used data from all National Health Service and private hospitals in England and Wales that submit data to the National Adult Cardiac Surgery Audit (NACSA). All patients undergoing first-time elective and urgent aortic valve replacement surgery (with or without coronary artery bypass grafting) with a biological (n = 15 series) or mechanical (n = 10 series) prosthetic valve from 5 primary suppliers, and satisfying prespecified data quality criteria (n = 43 782 biological; n = 11 084 mechanical) between 1998 and 2013 were included. Valves were classified into series of related models. Outcome tracking was performed using multifaceted record linkage. The median follow-up was 4.1 years (maximum, 15.3 years). Cox proportional hazards regression with random effects (frailty models) were used to model valve effects on the outcomes, with and without adjustment for preoperative and intraoperative covariates.Time to all-cause mortality or aortic valve reintervention (surgical or transcatheter). There were 13 104 deaths and 723 reinterventions during follow-up.Of 79 345 isolated aortic valve replacement procedures with or without coronary artery bypass grafting, 54 866 were analyzed. Biological valve implantation rates increased from 59% in 1998 and 1999 to 86% in 2012 and 2013. Two series of valves associated with significantly increased hazard of death or reintervention were identified (first series: frailty, 1.18; 95% prediction interval [PI], 1.06-1.32 and second series: frailty, 1.19; 95% PI, 1.09-1.31). These results were robust to covariate adjustment and sensitivity analyses. There were 3 prosthetic valves with a significant reduction in hazard (valve 1: frailty, 0.88; 95% PI, 0.80-0.96; valve 2: frailty, 0.88; 95% PI, 0.80-0.96; and valve 3: frailty, 0.88; 95% PI, 0.78-0.98).Meaningful evidence from the analysis of routinely collected registry data can inform postmarket surveillance of medical devices. Although the findings are associated with a number of caveats, 2 specific biological aortic valve series identified in this study may warrant further investigation.
FRI0613-HPR Do Physiotherapists Document Weight and Discuss The Influence of Weight on Pathology in Patients with Osteoarthritis?
Authors: A. Brennan, M. Maria, P. Robinson, M. Fitzgerald, H. Nolan, E. Sheehy, A. Curley, E. Lee Moloney, R. McCullom, C. Kelleher, C. Ni She
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> There is a strong association between increased body weight and osteoarthritis (OA). The NICE (2014) and ACR (2012) guidelines strongly recommend that patients with OA consider weight loss if overweight. <h3>Objectives</h3> The aim of this audit was to investigate if physiotherapists treating patients with knee and lumbar-spine OA: i) Documented patients weight; ii) Discussed the role of increased weight on OA <h3>Methods</h3> An audit of seventy physiotherapy charts of patients attending physiotherapy in 2013 found that 15percent (knee) and 11percent (lumbar-spine) had their weight documented. The role of increased weight was discussed with 15percent (knee) and 11percent (lumbar-spine). A "BMI station" was set up to use with patients. A lifestyle education class was established. In 2015 a re-audit was carried out on patients who attended for physiotherapy in 2014. <h3>Results</h3> Seventy physiotherapy charts were randomly selected and included. The median age was 64years (knee) and 53years (lumbar-spine). Of these 7 were male and 23 female (knee), 17 were male and 19 female (lumbar-spine). Of these, 38percent (knee) and 31percent (lumbar-spine) had their weight documented. The role of increased weight was discussed with 19percent (n=7) (knee) and 22percent (n=8) (lumbar-spine). <h3>Conclusions</h3> Physiotherapists have improved in relation to documenting weight and discussing the role of increased weight on OA since the previous audit. However, it is evident that they do not regularly document weight in patients with knee and lumbar-spine OA or document if they advised patients regarding the role of weight management for the treatment of OA. Further strategies to address this are necessary. <h3>Disclosure of Interest</h3> None declared
Clonal Gammopathies, Immune Cytopenias and Autoimmune Thyroid Dysfunction Following Alemtuzumab Containing Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Mojtaba Akhtari, Kavita Raj, Wendy Ingram, Dragana Milojkovic, Ihab El-Hemaidi, Stephen Devereux, Antonio Pagliuca, Aloysius Ho, Ghulam Mufti
Journal: Blood (2004)
CD41+ and Vascular Endothelial (VE)-Cadherin+ Cells: Two Developmental Origins of Hematopoietic Cell Lineages That Show Different Hematogenic Potentials.
Authors: Kazuaki Hashimoto, Xin Huang, Yuri Shimoda, Guoyou Dai, Tetsuhiro Fujimoto, Hiroshi Sakamoto, Minetaro Ogawa
Journal: Blood (2005)
SAT0476 Vitamin D Supplementation in Liver Transplant Patients: Table 1
Authors: J.L. Valero Sanz, E. Grau Garcia, C. Molina Almela, I. Chalmeta Verdejo, I. Martinez Cordellat, C. Feced Olmos, R. Negueroles Albuixech, L. Gonzalez Puig, M.L. Muñoz Guillen, C. Nuñez-Cornejo Piquer, C. Alcañiz Escandell, J. Ivorra Cortes, J.A. Roman Ivorra
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Liver transplant patients are at risk of developing osteoporosis and vitamin D deficiency. This deficit can be correlated with an increase in the rate of bone destruction and a decrease in its formation. Intervention and prevention of vitamin D deficiency in transplant patients may be associated with a decrease in PTH and serum beta CTX, reducing bone destruction. <h3>Objectives</h3> The objective of this study was study the utility of vitamin D supplementation in patients undergoing liver transplantation in relation to bone destruction rate. <h3>Methods</h3> Since January 2012 we collected 54 patients undergoing liver transplantation, where data is available at transplant (month 0) and 6 month follow-up and 12 months after surgery. We collected data on vitamin D and biomarkers of bone resorption and bone formation. <h3>Results</h3> The 54 selected patients are 66% men, with a mean age at transplantation of 55 years. Vitamin D, PTH, and beta-CTX P1NP levels are shown in Table 1. In 49 of the 54 patients, a vitamin D supplement was administered (0.266 mg/15days) immediately after surgery, at 6 months (n=46) and 12 months (n=26). Improved vitamin D levels and normalization of the values of beta-CTX and P1NP were observed. Statistical analysis did not yield significant results, mainly due to the low number of samples available in our series. <h3>Conclusions</h3> In general, there is a normalization of serum vitamin D levels and biomarkers of bone resorption and bone formation after a year of treatment with vitamin D supplementation after surgery. This study is at an early stage, so the sample size needs to be expanded in order for statistical analysis to provide greater robustness. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5072
HCP-17RETROSPECTIVE ANALYSIS OF PNEUMOCYSTIS JIROVECI IN BRAIN TUMOR PATIENTS
Authors: Catherine Maurice, Caroline Chung, Warren Mason
Journal: Neuro-Oncology (2015)

Pneumocystis jiroveci pneumonia (PCP) can be a highly lethal infection in patients with HIV or other immunodeficiencies, with a mortality rate estimated at 50%. The use of corticosteroids has been associated with 80-94% of PCP cases in the non-HIV population. In two-thirds of cases, the infection clinically presents during the tapering of steroids, likely reflecting an infection that is unmasked as the patient regains the ability to mount an immune response. The precise influence of dose and duration of corticosteroid treatment regarding susceptibility to PCP infection remains a controversial question. Some studies suggest that patients with brain tumors on steroids for more than 5 weeks are at high risk of PCP, especially during the tapering period. Generally, patients who receive steroid treatment for more than 4 weeks at a dose equivalent to 20 mg of prednisone per day are considered for PCP prophylaxis at most cancer centres, but there is variability across institutions. At the Pencer Brain Tumor Centre at Princess Margaret, there is no established protocol regarding PCP prophylaxis in glioma patients on corticosteroids, as it is felt that the incidence of PCP is rare and side effects of prophylaxis can impact patient's overall well being during treatment. Retrospective assessment of our cohort of patients with primary brain tumors from January 1st 2008 to December 31st 2013 will help determine the incidence of PCP infection in this population in the absence of prophylaxis and will allow evaluation of factors associated with PCP infection, including the dose and the duration of corticosteroid treatment, CD4 count and systemic therapy. We will also determine the proportion of patients who needed to stop their PCP prophylaxis due to side effects and the correlation between PCP infections and the duration/dose of steroid treatment. Results will be available for the SNO meeting.
A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL).
Authors: Owen A O'Connor, J. Gerecitano, H. Van Deventer, B. Afanasyev, J. Hainsworth, M. Chen, K. Saikali, J. Seroogy, R. Escandon, A. Wolff, MG. Conlan
Journal: Blood (2009)
THU0257 Diagnostic Accuracy of Multiplex Bead-Based Immunoassay for Antinuclear Antibodies (ANA) Testing in Systemic Lupus Erythematosus (SLE)
Authors: E. Aleksandrova, Z. Verijnikova, A. Novikov, T. Panafidina, N. Seredavkina, T. Popkova, N. Ayzina, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> ANA are a large family of autoantibodies directed at various cellular constituents. The measurement of ANA is a useful tool to confirm the diagnosis of SLE. New automated bead-based arrays can simultaneously and rapidly determine a profile of multiple ANA. Clinical performance of multiplexed technologies for detection of ANA specificities in SLE is not validated. <h3>Objectives</h3> To evaluate the diagnostic accuracy of multiplex bead-based immunoassay for the detection of ANA profile in SLE. <h3>Methods</h3> We studied 94 patients (pts) (80 F, age 35.9 [16.0–65.0] years, disease duration 113.5 [2.0–576.0] months) with SLE (ACR criteria, 1997), 50 pts with other systemic autoimmune rheumatic diseases, 20 pts with non-autoimmune rheumatic diseases and 30 healthy controls. Serum samples were analyzed for SLE-associated ANA (anti-dsDNA, anti-Sm, anti-chromatin, anti-SS-A/Ro 52 kDa and 60 kDa, anti-SS-B/La, anti-RNP-70, anti-ribosomal P) using automated multiplex bead-based immunoassay system BioPlex® 2200 (ANA Screen; Bio-Rad Laboratories Inc., USA). The following ANA values were considered positive: anti-dsDNA≥10.0 IU/mL, other antigen-specific ANA ≥1.0 AI (Antibody Index). <h3>Results</h3> The detection of anti-dsDNA, anti-Sm, anti-ribosomal P antibodies by BioPlex assay demonstrated the highest overall specificity (0.95, 0.97, 0.99, respectively), and positive likelihood ratio (LR) (10.40, 9.67, 15.0, respectively) for diagnosis of SLE (Table 1). BioPlex assay for anti-RNP-70, anti-SS-A/Ro, anti-chromatin antibodies was a useful diagnostic test in SLE (positive LR 2.80, 2.31, 4.15, respectively). Anti-SS-B/La antibodies testing had no value in SLE diagnosis (positive LR 1.20). The frequency of 1 ANA in SLE pts was 79.8%,2 ANA – 28.7%, 3 ANA – 15.6%, 4 ANA – 10.6%, 5 ANA – 5.3%, 6 ANA – 1.1%. Simultaneous detection of ≥3 ANA increased the specificity of multiplex immunoassay up to 0.98–1.00, and positive LR – to a maximum value. <h3>Conclusions</h3> The detection of ANA profile by multiplex bead-based immunoassay has a high specificity and positive likelihood ratio for diagnosis of SLE. Additional investigations are required to evaluate the usefulness of multiplex ANA testing for monitoring disease activity and for determining prognosis of SLE. <h3>Disclosure of Interest</h3> None declared
OC-045 Treatment Outcomes of Large Rectal Polyps at a Single Tertiary Health Centre in the UK
Authors: S Al-Rubaye, M Kelly, N Ladep, S Slawik, S Ahmed
Journal: Gut (2016)

<h3>Introduction</h3> Large (&gt;2 cm) rectal adenomas are currently treated by trans-anal endoscopic microsurgery (TEMS) or endoscopic mucosal resection (EMR). The aim of this study is to report on the effectiveness, safety and final outcome of both procedures in patients at a single tertiary health centre in the UK. <h3>Methods</h3> A cross-sectional study comparing patients and polyps specific variables in patients that underwent transanal endoscopic resection (TEMS) or endoscopic mucosal resection (EMR) for large rectal polyps, during 2011 to 2015. The data was obtained from colorectal multidisciplinary team (MDT) records, supplemented by information from the endoscopy reporting tool of the Hospital (Unisoft®). Variables analysed included polyp size, patient’s age and gender, procedure complication rate, success and failure rate. We also looked for the number for emergency admission needed. Chi-squared test was used to compare rates of examined variables between both techniques. <h3>Results</h3> Fifty four patients (mean age 74 ± 10.8) underwent EMR whilst fifty three patients (mean age 68 ± 11) had TEMS. Male: female ratio was 1:2 respectively (p value =0.16). Mean polyp sizes were 3 cm (range 2–10 cm) and 3.5 cm (range 2–10 cm) for EMR and TEMS, respectively (p value 0.4). The success rates of both procedures were comparable (92.6% and 88.7% for EMR and TEMS respectively). On the contrary, complication rate was slightly higher in those that had TEMS: 5.7% (1.9% post EMR, p value 0.29). We observed in our study that 9.4% of those who had TEMS required second, high risk surgery (3.7% had Anterior resection, 3.7% required Extralevator abdominoperineal excision ELAPE and 1.8% had Hartman’s surgery). 37% of patients underwent EMR polypectomy required second procedure (further EMR or TEMS) for complete excision. There was a significantly higher recurrence rate post EMR than post TEMS (34% and 7.4% respectively, p0.001) <h3>Conclusion</h3> In this single tertiary centre, both EMR and TEMS offered similar effectiveness in the treatment of large rectal polyps. The higher recurrence rate of polyps post EMR relative to TEMS engenders further investigation. <h3>Disclosure of Interest</h3> None Declared
The t(14;19)(q32;q13) Translocation in B Lymphoproliferative Disorders: A Continuum from Chronic Lymphocytic Leukemia (CLL) to Marginal Zone Lymphoma (MZL)?.
Authors: Florence Nguyen-Khac, Elise Chapiro, Isabelle Radford-Weiss, Christian Bastard, Leroux Dominique, Evelyne Callet-Bauchu, Pascaline Talmant, Isabelle Luquet, Mozziconacci Marie-Joelle, Lessard Michel, Raynaud D. Sophie, Frederic Davi, Helene Merle-Beral, Francoise Berger, Roland Berger
Journal: Blood (2006)
Disturbed CXCR4/CXCL12 Axis In Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia
Authors: Lieke C.J. van den Berk, Arian van der Veer, Marieke E. Willemse, Myrte J.G.A. Theeuwes, Mirjam W. Luijendijk, Wing H. Tong, Inge M. van der Sluis, Rob Pieters, Monique L. den Boer
Journal: Blood (2013)
Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis
Authors: Sajitha Sachchithanantham, Anna Baginska, Dorota Rowczenio, Shameem Mahmood, Rabya Sayed, Ketna Patel, Thirusha Lane, Lisa Rannigan, Darren Foard, Carol Whelan, Helen Lachmann, Julian D Gillmore, Philip N Hawkins, Ashutosh Wechalekar
Journal: Blood (2013)
SP0073 Empowering Young People with Rmd To Find Their Voice and Claim Their Space
Authors: I.A. Murphy
Journal: Annals of the Rheumatic Diseases (2016)

The presentation will focus on empowering young people in relation to their condition and through participation in local, national and international structures. The importance of empowering young people to self manage their condition and navigate transitions in their lives will be explored in the context of their holistic development. The second element of the presentation will focus on participation of young people in RMD related organisations. The key model of participation will be that of Professor Laura Lundy: SPACE, VOICE, AUDIENCE and INFLUENCE and how this can be facilitated in existing organisations. Practice examples will be included. The presenter contends that the engagement of young people in RMD structures will lead to better individual outcomes and enrich existing organisations. <h3>Disclosure of Interest</h3> None declared
Analysis of the Impact of Donor-Recipient ABO Mismatch on Outcomes of HLA-Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)
Authors: Praveen Ramakrishnan Geethakumari, Thomas R. Klumpp, Rachael Grosso, Ashok Mandala, Neal Flomenberg, Dolores Grosso
Journal: Blood (2015)